Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 10.67B | 10.67B | 9.58B | 8.12B | 8.99B | 6.84B |
Gross Profit | 2.65B | 2.65B | 2.48B | 2.76B | 2.43B | 1.89B |
EBITDA | 1.12B | 1.34B | 1.62B | 1.76B | 1.57B | 981.00M |
Net Income | 452.69M | 452.69M | 708.76M | 812.06M | 654.05M | 304.06M |
Balance Sheet | ||||||
Total Assets | 21.20B | 21.20B | 19.31B | 17.35B | 16.37B | 15.70B |
Cash, Cash Equivalents and Short-Term Investments | 3.29B | 3.29B | 3.60B | 2.83B | 2.37B | 2.02B |
Total Debt | 10.10B | 10.10B | 8.62B | 8.90B | 8.58B | 9.04B |
Total Liabilities | 11.96B | 11.96B | 10.72B | 10.49B | 10.40B | 10.38B |
Stockholders Equity | 9.14B | 9.14B | 8.49B | 6.79B | 5.89B | 5.29B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | -1.44B | 584.36M | 824.13M | 1.25B | -1.43B |
Operating Cash Flow | 0.00 | 21.92M | 1.66B | 1.99B | 2.41B | 297.16M |
Investing Cash Flow | 0.00 | -1.60B | -1.58B | -1.77B | -1.48B | -2.16B |
Financing Cash Flow | 0.00 | 1.27B | 638.92M | 240.73M | -534.92M | 928.54M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | ¥2.76B | 6.03 | 2.13% | 1.84% | 75.79% | ||
71 Outperform | ¥5.66B | 7.64 | 4.14% | -1.48% | -18.73% | ||
71 Outperform | ¥5.32B | 13.58 | 2.33% | -1.10% | 26.19% | ||
68 Neutral | $5.49B | 49.51 | 1.34% | 10.48% | -87.55% | ||
66 Neutral | ¥7.26B | 39.92 | 3.17% | -3.04% | -10.38% | ||
64 Neutral | $10.74B | 15.86 | 8.15% | 2.00% | 2.70% | -15.17% | |
60 Neutral | ¥4.58B | 28.44 | 3.34% | -0.55% | ― |
EnBio Holdings, Inc. reported its consolidated financial results for the fiscal year ended March 31, 2025, showing an increase in net sales by 11.4% to ¥10,668 million. However, the company experienced a decline in ordinary profit and profit attributable to owners of the parent by 34.2% and 36.1%, respectively. The financial results reflect challenges in maintaining profitability despite revenue growth. The inclusion of two new companies, DEFNE ENERGY INVESTMENT INDUSTRY TRADE LIMITED and EnBio C West, G.K., in its consolidation scope indicates strategic expansion efforts. The forecast for the next fiscal year predicts further growth in net sales and profits, suggesting a positive outlook for the company’s future performance.